Company* | Product | Description | Indication | Status |
CANCER |
||||
AEterna Laboratories Inc. (Canada; AELA; TSE:AEL) | Neovastat | Antiangiogenic product | Metastatic refractory prostate cancer | Phase I/II study results in 48 patients confirmed Neovastat's safety profile and dose-related activity (6/27) |
Amgen Inc. | Abarelix | Gonadotropin- | Prostate cancer | Phase III results demonstrated Abarelix's ability to reduce serum prostate-specific antigen and testosterone levels compared to standard hormone therapy (6/4) |
Bioniche Life Sciences Inc. (Canada; TSE:BNC) | MCC | Mycobacterial cell wall technology | Carcinoma in situ of the bladder | Phase I/II study results showed a 59% complete response to MCC, and a 65% positive response (6/25) |
Celgene Corp. (CELG) | Thalomid | Thalidomide; modulates levels of tumor necrosis factor-alpha | Metastatic colorectal cancer | Celgene initiated two studies evaluating the safety and efficacy of Thalomid in combination with Xeloda (6/1) |
Cell Genesys Inc. (CEGE) | GVAX | Lung cancer vaccine | Lung cancer | Company initiated a second multicenter Phase I/II trial (6/21) |
Corixa Corp. (CRXA) | Melacine | Vaccine consisting of lysed cells from two human melanoma cell lines combined with Corixa's Detox adjuvant | Stage II melanoma | Phase III data showed there was not a statistically significant improvement on disease-free survival, but among patients who express Class I major histocompatibility complex human leukocyte antigen A2 or C3 genes, Melacine does make a statistically significant improvement in disease-free survival (6/21) |
Dendreon Corp. (DNDN) | Provenge | Vaccine that appears to delay tumor progression | Prostate cancer | Company initiated a Phase III trial (6/11) |
Enzon Inc. (ENZN) and Schering- Plough Corp. | PEG-Intron | Injection; peginterferon alfa-2b | Chronic myelogenous leukemia | PEG-Intron did not meet the primary endpoint of non-inferiority in its study comparing it to Intron A (6/11) |
Genta Inc. (GNTA) | Genasense | Antisense compound geared toward blocking the production of Bcl-2 | Multiple myeloma and acute myeloid leukemia | In one study, Genasense decreased Bcl-2 protein in acute myeloid leukemia cells by 72 hours; in another study, it reduced Bcl-2 levels in myeloma cells; also, used in combination with Mylotarg, it increased cell death up to 63%, compared to treatment with Mylotarg alone (6/25) |
ILEX Oncology Inc. (ILXO) | ILX-651 and NM-3 | Synthetic pentapeptide analogue of dolastatin; orally active small molecule that inhibits angiogenesis by blocking the expression of vascular endothelial growth factor | Cancer | Company began enrollment in its Phase I trials (6/19) |
Immunomedics Inc. (IMMU) | Bispecific antibody | Composed of half of an anti-CEA antibody linked to half of another antibody targeting a carrier with a therapeutic isotope attached to it | Cancer | Phase I/II data showed no toxicity after the therapeutic isotope was given (6/27) |
Lorus Therapeutics | GTI-2501 | Antisense compound | Solid tumors or lymphoma | Company began a Phase I trial (6/11) |
Matrix Pharmaceutical | IntraDose | Cisplatin/epinephrine injectable gel | Primary liver cancer | Began enrollment in a Phase II study (6/28) |
Matrix Pharmaceutical Inc. (MATX) | IntraDose | Cisplatin/epinephrine injectable gel | Head and neck cancer |
Company initiated a study of IntraDose used in combination with other chemotherapeutic agents (6/21) |
MediGene AG (Germany; Neuer Markt:MDG) and | ¿ | Vaccine based on gene transfer by adenoassociated viruses | Malignant melanoma | Companies started a Phase I/II trial (6/25) |
MGI Pharma Inc. (MOGN) | Irofulven | Used in combination with Gemzar (gemcitabine hydrochloride) | Advanced cancers | Company initiated a Phase I trial (6/19) |
Millennium Pharmaceuticals Inc. (MLNM) | LDP-341 | Acts against cancer cells by blocking proteasome function | Chronic lymphocytic leukemia | Company initiated a Phase II trial of LDP-341; it also initiated Phase I trials testing it in combination with gemcitabine and irinotecan (6/15) |
Novuspharma SpA (Italy; Nuovo Mercato:NOV) | BBR 3464 | Novel tri-platinum complex | Advanced pancreatic cancer | Recruitment began for a Phase II trial (6/21) |
Peregrine Pharmaceuticals Inc. (PPHM) | Cotara | Radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill tumors from the inside out | Primary and unresectable cancers of the pancreas, liver, prostate or brain | Company presented Phase I/II results showing the drug was well tolerated and displayed positive results (6/26) |
Protarga Inc.* | Taxoprexin DHA-paclitaxel | Synthetic small molecule made by chemically linking paclitaxel to the natural fatty acid docosahexaenoic acid | Advanced renal cell carcinoma | Company began a Phase II study (6/6) |
Ribozyme Pharmaceuticals Inc. (RZYM) and Chiron Corp. (CHIR) | Angiozyme | Antiangiogenic; ribozyme that targets the high- affinity receptor for vascular endothelial growth factor | Metastatic colorectal cancer | Companies initiated treatment of the first patient in a Phase II trial (6/20) |
Supergen Inc. (SUPG) | Rubitecan | Oral chemotherapy compound | Pancreatic cancer | Company completed patient enrollment for its second of three pivotal Phase III studies (6/12) |
Telik Inc. (TELK) | TLK286 | Small-molecule drug that targets tumors that overexpress GST P1-1 | Non-small-cell lung cancer | Company started a Phase II trial (6/28) |
Titan Pharmaceuticals Inc. (AMEX:TTP) | CeaVac | Monoclonal antibody that induces an immune response to the carcino- embryonic antigen | Advanced colorectal cancer | Company completed enrollment in its Phase III study of CeaVac (6/19) |
CARDIOVASCULAR |
||||
Centocor Inc.* | Retavase and ReoPro | A clot-dissolving fibrinolytic agent and abciximab, an anticlotting agent | Heart attack | Phase III results evaluating half the dose of Retavase and a standard dose of ReoPro showed reduced complications, including the recurrence of heart attack and the need for urgent procedures to open coronary arteries (6/15) |
Collateral Therapeutics Inc. (CLTX) and Schering AG | Generx | Nonsurgical angiogenic gene therapy | Stable exertional angina due to coronary artery disease | Companies plan to initiate two Phase IIb/III trials (6/18) |
Corvas International Inc. (CVAS) | Nematode | Injectable anticoagulant, recombinant Nematode Anticoagulant Protein c2 | Elective percutaneous transluminal coronary angioplasty | Company completed enrollment in its Phase IIa study (6/6) |
CV Therapeutics Inc. (CVTX) | CVT-510 | A selective A1 adenosine receptor agonist | Paroxysmal supraventricular tachycardia | Company initiated a Phase III trial (6/29) |
The Medicines Co. (MDCO) | Angiomax | Bivalirudin; anticoagulant | Patients undergoing angioplasty | Phase IIIb/IV results showed patients receiving Angiomax experienced fewer complications than patients receiving heparin (6/8) |
Valentis Inc. (VLTS) | VLTS-589 | Human Del-1 gene medicine for angiogenesis | Peripheral arterial disease | Company initiated patient enrollment in a Phase I/II study (6/13) |
Vasogen Inc. (Canada; AMEX:MEW; TSE:VAS) | ¿ | Immune modulation therapy | Congestive heart failure | Company completed patient enrollment in a clinical trial (6/26) |
CENTRAL NERVOUS SYSTEM |
||||
Axonyx Inc. (AXYX) | Phenserine | Highly selective and reversible inhibitor of the enzyme acetylchol- inesterase | Alzheimer's disease | Company completed patient enrollment in its Phase II trial (6/28) |
Drug Royalty Corp. Inc. (Canada; TSE:DRI) and | D2E7 | Fully human monoclonal antibody tested in combination with methotrexate | Rheumatoid arthritis | All three doses reduced the signs and symptoms of RA in a study involving 271 patients (6/21) |
Durect Corp. (DRRX) | Chronogesic (formerly DUROS sufentanil) | Three-month continuous infusion subcutaneous implant | Chronic pain | Phase II results were positive (6/29) |
Interferon Sciences Inc. (OTC BB:IFSC) | Alferon N | Interferon alfa-n3 | Multiple sclerosis | Company presented positive results showing two out of 31 patients in the treatment group had gadolinium-enhanced lesions in the brain, while 14 out of 38 patients did in the untreated group (6/26) |
NicOx SA (France; Nouveau Marche: NICOX) | NCX 701 | Nitric oxide-releasing derivative of paracetamol (acetaminophen) | Pain and fever | Positive Phase I results showed the drug to be well tolerated and absorbed at all doses tested (6/27) |
Repligen Corp. (RGEN) | ¿ | Human synthetic secretin | Autism | Company initiated an open-label extension of the Phase II trial in children who failed to reach the trial's primary endpoint (6/19) |
Serono SA (Switzerland; NYSE:SRA) | Rebif | Recombinant interferon beta-1a | Relapsing- remitting multiple sclerosis | Results presented showed Rebif patients had a 90% greater chance of remaining relapse-free relative to patients treated with Biogen Inc.'s Avonex, which has orphan drug status; Biogen disputed finding (6/22) |
Shire Pharmaceuticals Group plc (UK) | CX516 | Ampakine CX516 | Attention deficit hyperactivity disorder | Companies will initate enrollment in a Phase II study (6/13) |
Symbollon Pharmaceuticals Inc. (SYMBA) | IoGen | Molecular iodine | Pain and tenderness associated with fibrocystic breast disease | Company expects to begin enrolling patients in a Phase III trial in the first quarter of 2002 (6/26) |
DIABETES |
||||
Alkermes Inc. (ALKS) | Inhaled insulin | Based on Alkermes' AIR pulmonary drug delivery system | Diabetes | Phase I data showed a rapid onset of therapeutic action, dose-dependent glucose-lowering ability and competitive biopotency (6/25) |
Amylin Pharmaceuticals Inc. (AMLN) | AC2993 | Synthetic exendin-4 | Diabetes | Company said AC2993 produced a statistically significant lowering of fructosamine in a 28-day study and all dosing arms achieved a statistically significant improvement in glycated hemoglobin levels (6/20); company said the data support progression of AC2993 into Phase III (6/25) |
DepoMed Inc. (AMEX:DMI) | Metformin GR | Once-daily treatment that uses DepoMed's gastric retention technology | Type II diabetes | Company started a Phase III trial (6/21) |
Inhale Therapeutic Systems Inc. (INHL) | Exubera | Inhaled insulin | Type I and Type II diabetes | Phase III data showed more patients treated with inhaled insulin achieved the recommended blood glucose levels than patients who received only insulin injections (6/25) |
Nobex Corp.* | ¿ | Oral insulin product | Type I and Type II diabetes | Phase II results showed positive safety and efficacy trends (6/26) |
INFECTION |
||||
CV Technologies Inc. (Canada; | CVT-E002 | A multicomponent phytopharmaceutical | Upper respiratory infections | Company completed a Phase II trial (6/26) |
Gilead Sciences Inc. (GILD) | Adefovir dipivoxil | Antiviral reverse transcriptase inhibitor | Naove chronic hepatitis B | Interim Phase III data of adefovir dipivoxil showed no resistance mutations and met its endpoints of liver histology improvement; it also showed no kidney toxicity (6/22) |
GenStar Therapeutics (AMEX:GNT) | Maximum-AD | Engineered to optimize Factor VIII expression in the liver | Hemophilia A | Company initiated a Phase I gene therapy trial (6/18) |
Hemispherx Biopharma Inc. (AMEX:HEB) | Ampligen | Double-stranded synthetic RNA compound poly 1; poly C124 | HIV | Company commenced treatment cycles in two new Phase IIb trials with Ampligen, designed to overcome and/or prevent multidrug-resistant HIV (6/14) |
Isis Pharmaceuticals Inc. (ISIP) | ISIS 14803 | Antisense drug; 20-base phosphorothioate oligonucleotide | Drug-resistant chronic hepatitis C | A Phase I/II trial with 11 patients demonstrated dose-dependent antiviral activity (6/18) |
Palatin Technologies Inc. (AMEX:PTN) | LeuTech | Radiolabeled monoclonal antibody intended to image and diagnose sites of infection | Osteomyelitis | Phase II results showed LeuTech to be well tolerated and superior to both indium oxine-labeled white blood cells and 3-phase bone scans (6/25) |
Transkaryotic Therapies Inc. (TKTX) | Factor VIII | Gene therapy | Hemophilia A | Phase I results showed the nonviral ex vivo gene therapy system delivering Factor VIII was safe and well tolerated (6/6) |
Trimeris Inc. (TRMS) | T20 | Fusion inhibitor | HIV | Completed patient enrollment in a Phase III trial (6/28) |
Versicor Inc. (VERS) | Anidulafungin | Intravenous infusion | Candidiasis/ candidemia | Company started a Phase II trial (6/26) |
MISCELLANEOUS |
||||
Adolor Corp. (ADLR) | ADL8-2698 | Gastrointestinal tract- restricted opioid narcotic antagonist | Bowel dysfunction | Phase II trial showed positive results (6/29) |
Alexion Pharmaceuticals Inc. (ALXN) | 5G1.1 | Humanized monoclonal antibody C5 complement inhibitor | Lupus nephritis | Company began a Phase II trial (6/7) |
Genentech Inc. (NYSE:DNA) | Xanelim | Humanized monoclonal antibody | Psoriasis | Phase III trial results were positive (6/21) |
Genzyme General (GENZ) | Renagel | Calcium-based phosphate binders to control serum phosphorous levels | End-stage renal disease | Data from a three-year trial showed patients experienced a 25% increase in their coronary artery calcification scores after one year of taking calcium-based phosphate binders, while patients taking Renagel experienced a 6% increase (6/26) |
InKine Pharmaceutical Co. Inc. (INKP) | Colirest | Oral steroid molecule; Fc receptor technology | Crohn's disease | Company enrolled the first patient for treatment in the pivotal Phase II trial (6/25) |
Isis Pharmaceuticals | ISIS 104838 | Inhibitor of tumor necrosis factor-alpha | Psoriasis | Company initiated a Phase II trial (6/21) |
ISTA Pharmaceuticals Inc. (ISTA) | Vitrase | Injectable enzyme; hyaluronidase | Vitreous hemorrhage | Company completed patient patient enrollment in one of two Phase III trials (6/28) |
Lilly ICOS LLC (joint venture of ICOS Corp. [ICOS] | Cialis | Inhibits PDE5 | Erectile dysfunction | Phase III results showed 85% of patients experienced improved erections (6/1) |
Lilly ICOS LLC (joint venture of ICOS Corp. [ICOS] | IC351 | Inhibits cGMP-destroying enzyme PDE5 | Female sexual arousal disorder | Trial results showed no conclusive treatment effect relative to placebo (6/18) |
MedImmune Inc. (MEDI) and BioTransplant | MEDI-507 | Siplizumab | Psoriasis | Phase I and Phase I/II trial results showed the drug was generally safe and well tolerated (6/25) |
Millennium Pharmaceuticals Inc. (MLNM) | LDP-977 | Orally active second- generation 5-lipoxygenase inhibitor | Asthma | Company initiated a Phase II trial (6/12) |
Miravant Medical | MV9411 | PhotoPoint drug | Skin disorders | Company completed enrollment in the Phase I trial (6/14) |
Nastech Pharmaceutical Co. (NSTK) | Apomorphine | Intranasal formulation | Erectile dysfunction | Interim Phase II results indicated a dose of the drug allowed successful intercourse 80% of the time (6/5) |
Nastech Pharmaceutical | Apomorphine | Intranasal formulation | Female sexual dysfunction | Company initiated a Phase II at-home trial in 75 women (6/12) |
NeoTherapeutics Inc. (NEOT) | Neotrofin | Nerve regeneration drug | Spinal cord | Company expanded its Phase II trial (6/29) |
NexMed Inc. (NEXM) | Alprox-TD | Cream that combines alprostadil and NexACT transdermal deliverytechnology | Erectile dysfunction | Phase II results showed the cream produced between a 59% and an 83% improvement in erections (6/4) |
SangStat Inc. (SANG) | RDP58 | Novel peptide that inhibits tumor necrosis factor synthesis | Inflammation | Company initiated a Phase I study (6/18) |
Sepracor Inc. (SEPR) | (S)oxybutynin | Sustained-release formulation | Overactive bladder | Company initiated a 12-week Phase III study with 850 patients (6/20) |
Texas Biotechnology | Biomosiamose | Inhaled formulation; a selectin antagonist | Asthma | Phase I trial was initiated (6/26) |
Theratechnologies Inc. (Canada; | ThGRF | Peptide; a growth hormone-releasing factor analogue | Insomnia | Company began enrollment for its second Phase II trial (6/27) |
Zonagen Inc. (ZONA) | Bimexes | Combination oral product | Impotence | Phase II results comparing the product to Viagra showed no statistically significant differences (6/13) |
Zonagen Inc. (ZONA) | ERxin | Penile injection product | Impotence | Phase II results indicated the treatment with a bimix of phentolamine and prostaglandin or a trimix containing ohentolamine, papavarine and prostaglandin produced erections in 43% of test subjects at the lowest dose (6/20) |
Notes: |
||||
* Privately held |
||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. |
||||
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |